American University of Beirut Lebanon
Dr. Fadlo R. Khuri is the 16th President of the American University of Beirut University (AUB) and Professor of Medicine (Hematology and Medical Oncology) at the Faculty of Medicine and Medical Center. He assumed office on September 1, 2015. He was Professor and Chairman of the Department of Hematology and Medical Oncology, Emory University School of Medicine, and held the Roberto C. Goizueta Distinguished Chair for Cancer Research. He also served as Deputy Director for the Winship Cancer Institute of Emory University. Dr. Khuri was also the Executive Associate Dean for Research of the Emory University School of Medicine.
Dr. Khuri was born in Boston, MA and raised in Beirut while his father Raja N. Khuri served as dean of the AUB’s Faculty of Medicine and his mother as a professor of mathematics at AUB. Following a year of study at AUB (1981-82), Dr. Khuri earned his undergraduate degree at Yale University in New Haven, and his MD at Columbia University, College of Physicians and Surgeons in New York. He completed his residency in Internal Medicine at the Boston City Hospital, and a fellowship in Hematology and Medical Oncology at the Tufts-New England Medical Center. He was on faculty at the U.T. M.D. Anderson Cancer Center from 1995-2002 prior to joining Emory University and the Winship Cancer Institute (Winship) in 2003.
Dr. Khuri is an accomplished molecular oncologist and translational thought leader, his clinical expertise and research are focused on the development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with lung and aerodigestive cancers. He has authored over 350 peer-reviewed articles and over 50 editorials and perspectives in leading journals, and written over 100 reviews and chapters. He has served for the last six years as Editor-in-Chief of Cancer, the oldest and one of the most prestigious journals in the field. His scientific work has been cited over 30,000 times according to Google Scholar, and over 17,000 times by Web of Science, where his Hirsch index is 77. Dr. Khuri has also served as a permanent member of multiple peer review committees for the American Cancer Society, American Society of Clinical Oncology, and the NCI, including currently serving as the Chair of the NIH’s Clinical Oncology Study Section. He is an active member of the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer, the American Society for Clinical Investigation, and the American Society of Clinical Oncology.
Dr. Khuri’s ability to build teams with the singular vision of improving outcomes for cancer patients has helped develop Winship into a premier translational research engine. Dr. Khuri has led the recruitment of over 90 faculty including 60 clinical investigators to Emory University, helping oversee an increase in adult cancer patients placed on trial annually from 143 in 2002 to over 650 in 2014, and paving the way for NCI designation for the Winship.
Dr. Khuri’s work has been recognized with several major awards, including the 2006 Nagi Sahyoun Award of the Middle East Medical Assembly for “research that has changed the way we think about and treat lung and head and neck cancer”, the 2010 Waun Ki Hong Distinguished Professorship by the University of Texas MD Anderson, and the 2013 Richard and Hinda Rosenthal Memorial Award from the AACR for “his pioneering work in developing oncolytic viruses, signal transduction inhibitors, and biomarker based chemoprevention approaches to lung and aerodigestive cancers.” In 2013, Khuri was also recognized with the Arab American High Achievers (AAHA) Award by the Alif Society, the major Arab Cultural Foundation of Georgia. He is an elected member of the American Society for Clinical Investigation (2007), and a Fellow of the American College of Physicians (2009) and the American Association for the Advancement of Science (2015). He has been listed among America’s Top Doctors by Castle Connolly for the last 10 years.